Introduction
Heat shock protein 27 (Hsp27) belongs to the family of 'survival proteins', which also includes other members of Hsp family, anti-apoptotic BH3, survivin and IAPs family. This stress protein can interfere with a pleiotropic number of cell death pathways induced by heat shock, oxidative stress or death receptor agonist (Mehlen et al., 1996; Arrigo et al., 2005) . Hsp27 directly interferes with upstream events or key components of the apoptotic cascade like cytochrome-c release from mitochondria, procaspase 3 or DAXX, a mediator protein on Fas/Apo1-induced apoptosis (Charette and Landry, 2000; Pandey et al., 2000; Bruey et al., 2000a) . Hsp27 can modulate cell proliferation by interacting with the Akt pathway, which has an important role for the survival of many types of cancer cells (Rane et al., 2003) . Expression of Hsp27 is upregulated in numerous types of tumors (particularly breast, colon, ovarian and head and neck tumors) and promotes unfavorable outcome (Ciocca and Calderwood, 2005) . Overexpression of this protein is frequently associated with increased resistance to radiotherapy and to anti-cancer drugs, such as cisplatin, doxorubicin and etoposide (Hansen et al., 1999; Kim et al., 2007; Zhang and Shen, 2007) . Others and we have shown that targeting Hsp27 by antisense strategy increases cancer cell death in vitro and in vivo (Aloy et al., 2008; Matsui et al., 2009) .
Hsp27 pleiotropic functions are dependent on its three-dimensional structure. Hsp27, like the other members of the small Hsp family, presents an a-crystallin domain and can form different oligomeric structures of variable size, from 27 to 800 kDa. This phenomenon depends on the phosphorylation status of three serine residues, mostly controlled by the MAP-KAPK2, 3 (Landry et al., 1992) . Every oligomeric form may display a different role, present various biochemical functions and interact with multiple partners. Disturbing these oligomeric structures allows to interfere with Hsp27 biochemical properties and may inhibit tumor growth.
As antisense technologies are not easy to handle in vivo, the use of specific peptides that inhibit the anti-apoptotic activity of Hsp27 by interfering with its biochemical properties without altering its level of expression could lead to a new approach for anti-cancer therapies. We have previously shown that dominantnegative mutants of the protein disrupt several functions of Hsp27 (Diaz-Latoud et al., 2005) . Here, we used a new approach to specifically target and inhibit Hsp27. Peptide aptamers (PAs) are made of short peptides of random sequence inserted into a scaffold protein (here, the thioredoxin A ( ¼ TrxA) of Escherichia coli). The role of the scaffold is to display a conformationally constrained sequence of amino acids and to stabilize them in the cellular environment. PAs can specifically bind to and modulate the activities of a wide range of intracellular proteins, including oncogenes, transcription factors, cell cycle regulators and others (Buerger et al., 2003; Chattopadhyay et al., 2006; Nouvion et al., 2007) .
In this study, we characterized two aptamers that functionally inhibit Hsp27 and sensitize cancer cells to apoptosis in vitro and in vivo by disrupting the biochemical functions of the protein. This study confirms that Hsp27 is a therapeutic target in cancer and provides promising guides for the discovery of chemical inhibitors of Hsp27.
Results

Selection of PAs interacting with Hsp27
In order to validate the use of Hsp27 in the yeast twohybrid method and to map crucial domains of this chaperone, interactions between Hsp27 and mutant forms of the protein were tested by a yeast two-hybrid approach (Figures 1a and b) . Strong Hsp27 homodimerization was observed, as well as interaction of wild-type Hsp27, with several mutant forms. In contrast, point mutant aB-crystallin-R120G, responsible for human myopathies and cataracts, and deletion mutant Hsp27D141-175 did not give a detectable interaction phenotype with LexA-Hsp27 (Figure 1b) (Vicart et al., 1998) . However, the weak interaction phenotypes observed with LexA-Hsp27D141-175 were not due to a lack of expression of this construct as shown by the interaction of this mutant with aptamer 54 (PA54) (Figure 1d ). Altogether, these results establish that the LexA-Hsp27 fusion protein is a well-behaved bait (that is, well expressed, properly folded, localized in the nucleus, and without a detectable transcriptional activity) that can thus be used for a yeast two-hybrid PA selection. They also show that the R120 residue and the region comprised between amino acids 141 and 175 are essential.
To identify Hsp27 interacting aptamers, a yeast twohybrid screening was performed using wild-type Hsp27 as bait and a mix of randomized 8-and 13-mer PA libraries as preys. Initially, 160 PAs that showed a yeast two-hybrid interaction phenotype with the LexA-Hsp27 construct were isolated from a screen of 11 Â 10 9 yeast colonies. The aptamer plasmids were recovered from yeast, and the interaction phenotypes were verified after retransformation and mating assays. Sequences of 50 aptamers showing strong interaction phenotypes with LexA-Hsp27 were determined, out of which 25 unique Peptide aptamers, inhibitors of Hsp27: new therapeutic agents B Gibert et al variable regions were identified (Figure 1c) . A consensus sequence I/LLRRL can be identified in 50% of the sequenced peptides. Although the screening was performed on an equal mix of 8-and 13-mer PA libraries, only 7 aptamers contain a 13-mer variable region and only one of them presents the consensus sequence. These 25 PAs were tested for their interaction with Hsp27 and various mutants, as shown in Figure 1d . The aptamers presented different profiles and strengths of interaction with Hsp27 wild-type and mutant forms, suggesting that they bind to different regions of the molecular surface of this protein. Aptamers presenting an interaction phenotype with aB-crystallin and/or aB-crystallin-R120G were removed from further studies because of their lack of specificity toward Hsp27 (Figure 1d ).
Inhibition of Hsp27 anti-apoptotic activity by PAs in HeLa cells
To identify aptamers that are able to counteract Hsp27 protective activity against apoptotic treatments, we tested the activity of the selected aptamers in HeLa cells. Twenty-two aptamer-coding sequences were subcloned into the pCINeo vector bearing a neomycin resistance gene. HeLa cells were transfected with either the pCINeo vectors encoding specific Hsp27 aptamers, three different non-specific control aptamers, or with a pCINeo vector encoding an short hairpin RNA (shRNA) directed against Hsp27 messenger RNA.
Transfected HeLa cells were treated for 12 h with 0.2 mmol/l staurosporine, caspases activation was determined and 10 PAs that are able to increase apoptosis efficiency were identified (data not shown). Among them, PA11 and PA50, displaying 13 and 8 amino acids in their variable region, respectively, were selected upon their high specificity of interaction with wild-type Hsp27 in yeast. Control experiments were performed to test whether PA expression in HeLa cells could induce a stress response. This was performed by analyzing the level of expression of Hsp60, 70 and 90 in cells transiently expressing PAs 11 and 50. As shown in Figure 2a , no significant increase in either major Hsp was observed.
A WST-1 test was performed to determine cell proliferation. In this transient expression experiment, PAs 11 and 50 induced a decrease of HeLa cell proliferation, whereas control aptamer and shRNA27 did not ( Figure 2b ).
Hsp27 has been reported to induce high resistance to some of the drugs used in chemotherapy (Hansen et al., 1999; Kim et al., 2007; Zhang and Shen, 2007) . To assess effects of PAs on drug response, HeLa cells transfected with PA11 or PA50 were treated for 18 h with cisplatin or doxorubicin. As shown in Figure 2c , a 20% increase in cell death was observed after cisplatin treatment. The increase was up to 50% after doxorubicin treatment of PA50 or shRNA-transfected cells. In contrast, control aptamer (PAc) or MsRNA27 did not induce a cell death increase as compared with mock-transfected cells. These results indicate that PAs interfere with Hsp27 cytoprotective properties as much as does an shRNA that reduced the expression level of Hsp27 below the detection threshold (Figure 2a ).
Studies were also performed with the kinase inhibitor staurosporine. As observed with doxorubicin, PAs strongly increased, from 50 to 80%, staurosporineinduced cell death (Figure 2d) . The effect was similar to that induced by the shRNA targeting Hsp27. The processing of executioner caspase 3 is a hallmark of apoptosis. To assess caspase 3 activation in cells expressing or not PAs, protein extracts were analyzed by immunoblot after a 4-h staurosporine treatment (Figure 2d ). The high level of processed fragments p17 and, to a lesser extent, p12 indicated that PAs are also able to counteract Hsp27 anti-apoptotic activity.
Determination of aptamer specificity
To demonstrate aptamers specificity toward Hsp27, we performed further experiments in Hsp27-depleted HeLa cells. For this, we used the HSh2.2 cells characterized by a constitutive 90% decrease of Hsp27, as compared with control HMs27 cells expressing a mismatch construct of the shRNA (Figure 3a ). HSh2.2 cells were transfected with PA11, PA50 or PAc, and cell death was determined after a staurosporine treatment (Figure 3b ). Apoptosis was increased in HSh2.2 cells when compared with control cell line, and transient expression of PA11 or PA50 did not modify this extent of apoptosis. This indicates that the increase of apoptosis induced by the aptamers results from their interaction with Hsp27, clearly demonstrating the specificity and the ability of aptamers to block Hsp27 anti-apoptotic activities.
Aptamers modify the biochemical properties of Hsp27
The protection induced by Hsp27 is highly correlated with its biochemical state (Bruey et al., 2000b) . To determine whether PAs could modify the properties of Hsp27, we first analyzed the oxidative stress-induced dimerization of the protein in non-reducing polyacrylamide gel electrophoresis ( Figure 4a ). As a positive control, we expressed Hsp27-C137A, a dominantnegative mutant that is able to disrupt Hsp27 dimerization (Diaz-Latoud et al., 2005) . The negative control PAc and PA11 did not induce any modification of the dimeric state of the protein. In contrast, PA50 expression strongly inhibited Hsp27 dimerization, to a much higher extent than that of Hsp27-C37A mutant.
To further characterize perturbations of Hsp27 biochemical properties, we tested the oligomerization pattern of Hsp27 in HeLa cells expressing PAs using size exclusion chromatography. For this experiment, we used myc-tagged PAs, to enhance the detection of PAs in elution fractions. As already shown in exponentially growing mock HeLa cells, Hsp27 was recovered in two major structures with heterogeneous native molecular masses, small oligomers (o400 kDa) and large oligomers (4400 kDa) (Figure 3b ) (Mehlen et al., 1997) . The non-interacting control aptamer, PAc, did not induce any modification of Hsp27 oligomerization profile. In PA11-transfected cells, we observed strong modifications in Hsp27 oligomerization pattern. Quantification of western blot pointed out that Hsp27 was redistributed in two distinct populations, with a singular elution profile when compared with the other profiles (Figure 3b, upper right panel) . Furthermore, only 31.4% of Hsp27 was detectable in the small oligomers (o400 kDa) (Figure 4b ). In contrast, PA50 transfection did not affect Hsp27 oligomerization pattern as shown by the western blot quantification profiles. These data indicate that although both PAs are able to counteract Hsp27 anti-apoptotic properties, different biochemical mechanisms may underlie this target protein inhibition.
To access the above-mentioned point, we next analyzed phosphorylation of Hsp27 using specific antibodies directed against the three phosphorylated serine residues of Hsp27 (Paul et al., 2010) . Phosphorylation was induced by doxorubicin or cisplatin treatments (Supplementary data 1) . In non-treated cells, transfection of aptamers did not dramatically modify phosphorylation of the three serine residues of Hsp27. It is worth noting that in non-treated cells, PA11 expression resulted in a total lack of S78 phosphorylation, whether this is related to the oligomerization changes observed in gel filtration assays is not known. In mock cells, S15 phosphorylation was induced only by doxorubicin treatment, whereas S78 phosphorylation was Peptide aptamers, inhibitors of Hsp27: new therapeutic agents B Gibert et al induced by both treatments. In contrast, no phosphorylation of S82 was observed after either treatment. Aptamers expression did not modify cisplatin-induced phosphorylation of S78 when compared with control cells. In contrast, PA11 and PA50 stimulated the doxorubicin-induced phosphorylation of S15 and S78 sites, respectively. These results indicate that PA11 and PA50 modify Hsp27 phosphorylation, and therefore probably alter the quaternary structure and functions of this protein (Supplementary data 1) (Paul et al., 2010) .
To confirm the interaction observed in yeast, we performed co-immunoprecipitation assays directly using fractions of sizing chromatography columns. Hsp27 was immunoprecipitated from the 200-kDa column fraction containing both Hsp27 and PAs. The presence of the aptamers was detected by immunoblots with an antimyc antibody (Figure 4c ). This experiment confirms the interaction between Hsp27 and PA11 and 50.
Inhibition of tumor growth by Hsp27 PAs
To assess the ability of PAs to inhibit tumor growth, we produced constitutively expressing PA clones in the head and neck squamous cell carcinoma (HNSCC) SQ20B cell line (Figure 5a) . We have previously shown that targeting Hsp27 by antisense approach sensitizes the radioresistant SQ20B cells to g-irradiation (Aloy et al., 2008) . To test the radiosensitizing effect of PAs, cell survival curves were established after irradiation of SQ20B-PAs and SQ20B-PAc control cells at doses varying between 1 and 8 Gy. PA 11 and 50 increased the clonogenic cell death after irradiation as revealed by an exponential decrease in the percentage of surviving cells (Figure 5b ). The survival fraction at 2 Gy (SF2), used as an index of radiosensitivity, shifted from 0.75 Gy in SQ20B-PAc cells to 0.40 and 0.51 Gy in SQ20B-PA11 and SQ20B-PA50 cell lines, respectively (Figure 5b) .
To better characterize PA-induced inhibition, we performed tumor xenograft studies by injecting PAexpressing cells (and RNAi27-expressing cells) in female NUDE mice and measuring tumor volume by external calipers weekly after injection (Figure 5c ). Each animal was also injected with the appropriate control (Ms27 for RNAi27, and PAc for PA11 and PA50) to circumvent inter-animal variability. PA11 and 50 cells showed a strongly reduced tumor growth of 80 and 50%, respectively, as compared with PAc cells (Figure 5d ). shRNA cells, used here as a positive control, displayed a reduced tumor growth but to a lesser extent than PAexpressing cells. These data indicate that targeting Hsp27 with PAs is more efficient in inhibiting Hsp27 tumorigenic activity than downregulating its expression with an shRNA. Peptide aptamers, inhibitors of Hsp27: new therapeutic agents B Gibert et al
Aptamers inhibit the proliferation of tumor xenografts
To define the mechanism of action of PA in inducing a reduced tumor growth inhibition, we performed immunohistochemical staining of Ki67 proliferation marker, Giemsa coloration and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) apoptosis assay ( Figure 6a ). Photomicrographs of tumor sections and quantification of Ki67 marker revealed that the lack of tumor development with PA11 and 50 was due to an alteration of proliferation process (Figures 6a and b) . We have previously reported that a Hsp27 RNAi induces a small delay in tumor progression, without modulation of the Ki67 marker (Hadchity et al., 2009) . Moreover, TUNEL assay on tumor section showed that PA11 and PA50 did not increase apoptosis, probably as a result of a lack of pro-apoptotic stimulation (Figure 6a ). Although PAs statistically modulated proliferation in cancer cell line, our data suggest that tumor environment of xenograft may have a crucial role in inhibition of tumor development in mice with SQ20B-PA11 and 50 cells. The above findings show that PA expression induces a reduced proliferation of SQ20B cells. We therefore investigated whether PAs could modulate cell cycle components. For this, we analyzed by western blot the expression level of cell cycle markers in the recessed tumors. As shown in Figure 6c , levels of p21-waf1, a cyclin-dependent kinase inhibitor, were increased in PA11-and 50-expressing tumors. In contrast, the level of p27, another cyclin-dependent kinase-inhibiting protein, was not affected. To decipher this p21-waf1 accumulation in xenografts, we performed western blot analysis of p21-waf1 level in the constitutively PAexpressing clones of SQ20B cells. As shown in Supplementary Figure 2b , an identical level of p21-waf1 protein was detected in cultured SQ20B PAc cells or SQ20B PA11 or 50 cells. This indicates that aptamers induce a modification of p21-waf1 expression that is restricted to the in vivo model. Hence, the phenomenon is probably a consequence of the tumor environment rather than a direct regulation by the aptamers of p21-waf1 expression.
Discussion
Hsp27 is an anti-apoptotic protein over-expressed in a variety of tumors (Ciocca and Calderwood, 2005) . Because of its cytoprotective and oncogenic properties, Hsp27 has emerged as a major therapeutic target in cancer therapy (Arrigo et al., 2007) . We have developed a PA approach to functionally target Hsp27 without modulating its expression. Table: SF2 ¼ survival fraction at 2 Gy. (c) Photographs of tumor xenografts in immunocompromised BALBc/ nude mice 9 weeks after implantation. Controls and Aptamers or shRNA expressing tumor cells were injected two by two in the inner thigh of mice (n ¼ 13 for each group of mice). (d) Tumor volume was determined by external caliper measurement once weekly after injection. Tumor volume was determined by external caliper measurements and results were expressed as mean±s.d. Statistical significance was determined by unpaired t-test, revealing *Po0.05 for comparison of control with RNAi27, PA11 or PA50 at all times.
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In this work, we have identified PAs that are able to interact with Hsp27. Two of them promoted apoptosis induced by different radio or chemotherapeutic treatments in HeLa or SQ20B cells to the same extent than a shRNA directed against Hsp27. Furthermore, apoptosis promotion by the aptamers resulted of a specific interaction with Hsp27, as aptamer expression in Hsp27-depleted cells were devoid of effects. In addition, PA11 and 50 counteracted Hsp27 pro-survival functions in vivo and strongly inhibited tumor growth. Interestingly, PAs were significantly more efficient than the shRNA27 to reduce tumor growth. Restricted tumor analysis suggested that cell cycle was blocked due to the upregulation of the tumor suppressor protein p21-waf1. This is in agreement with O'Callaghan observation in HCT116 colon carcinomas cells after Hsp27 depletion (O'Callaghan-Sunol et al., 2007) . Interestingly, this upregulation was restricted to the in vivo model and probably due to the tumor environment. In contrast, p27 expression level was not affected in our study, although Hsp27 has been shown to promote the ubiquitination and degradation of this cyclin-dependent kinase inhibitor (Parcellier et al., 2006) .
One of the major challenges of targeting Hsps in cancer therapy is the induction of expression of other Hsp genes, which show functional redundancy and can trigger compensatory mechanisms. The Hsp90 inhibitor 17-AAG is currently used in clinical trials for its antitumor activity. However, 17-AAG triggers the transcription and elevation of anti-apoptotic Hsp27, 70 and 90, which lead to chemoresistance of cancer cells (Cervantes-Gomez et al., 2009) . Interestingly, targeting Hsp27 by PAs did not modulate other Hsp levels, either in cells or in vivo (data not shown), thus validating Hsp27 as a highly promising target in oncology.
Two aptamers, PA11 and PA50, (13-mer and 8-mer variable regions, respectively) were further characterized because of their specific features. PA11 was the only selected aptamer displaying no interaction with Hsp27-D100G. PA50 presents the consensus hydrophobic sequence found in 50% of Hsp27 interacting aptamers isolated in this study. PA11 and PA50 interacted specifically with Hsp27 and did not present any interaction with aB-crystallin, an other member of small heat shock protein (sHsp) family sharing a strong conformational homology with Hsp27. Interestingly, those aptamers that did not interact with aB-crystallin did not present any interaction with Hsp27-R140G mutant (except for Apt166). This mutant was designed by homology with aB-crystallin-R120G responsible for human myopathies and cataracts (Vicart et al., 1998) . aB-crystallin-R120G did not present an interaction with any of the sHsp tested in our two-hybrid assays. Arginine 120 residue might be of importance for all Peptide aptamers, inhibitors of Hsp27: new therapeutic agents B Gibert et al sHsp-based interactions, strongly suggesting its implication in PA binding specificity.
To determine the mechanism of action of PAs, we studied the structural organization of Hsp27 in PAexpressing cells, as anticancerous properties of this sHsp rely on its oligomeric status. Although biochemical mechanisms underlying Hsp27 structural dynamic changes are not clearly understood yet, it has been shown that dimerization of protein monomers is a crucial event to form larger oligomers. PA50 was able to inhibit dimerization without disrupting Hsp27 large oligomers, thus mimicking the dominant-negative Hsp27-C137A mutant endowed with the ability to disrupt dimer formation and functional properties of wild-type Hsp27 without abolishing large oligomers formation (Diaz-Latoud et al., 2005) . Other PAs with the conserved amino-acid motif I/LLRRL tested in same conditions did not disrupt dimer formation of Hsp27 (data not shown). These data suggest that the cysteine residues in the variable region of PA50 are able to interfere with the formation of Hsp27 disulfide bridges. PA11 did not interfere with Hsp27 dimerization, but inhibited the turnover of oligomeric Hsp27 forms, as the oligomeric profile of Hsp27 was greatly modified in PA11-expressing cells. Interestingly, PAs were only detected in fractions containing small oligomeric forms of Hsp27, suggesting an interference with the dynamic structural organization of Hsp27 to form high oligomeric forms. This was confirmed by the observation that PA50 modified doxorubicin-induced phosphorylation of Hsp27. In addition, PAs were able to inhibit Hsp27 anti-apoptotic activity at different levels of conformational state. Hence, these data confirm that sHsp functions are dependent on the structural organization of these proteins, as exogenous molecules targeting Hsp27 monomers inhibit Hsp27-induced cellular protection by interfering with its conformational state.
In conclusion, our work demonstrates that PAs are able to interact with Hsp27 and to interfere with its biochemical properties, thus inducing apoptosis in cancerous cell line and inhibiting tumor proliferation in vivo. PAs may be exploited to specifically target Hsp27 and discover new insights into Hsp27 structurefunction relationship. The in silico search for molecules interfering with sHsps is a challenge, as the tridimensional structure of Hsp27 is unknown, because of the high difficulty to obtain stable crystals of the oligomeric form of this protein. Therefore, modeling of PAs docking sites may represent potential tools to initiate a screening that may help in the discovery of Hsp27 chemical inhibitors (Baines and Colas, 2006) .
Materials and methods
Reagents
Nonidet P-40, Triton X-100, desoxycholic acid, dithioerythritol, staurosporine, doxorubicin, cisplatin and G418 were from Sigma (Saint-Quentin Fallavier, France). Cell culture media and complements were from Invitrogen (Cergy Pontoise, France). Anti-caspase 3 was from Alexis Biochemical Qbiogen (Illkirsch, France). The primary antibodies were detected with either anti-rabbit or anti-mouse immunoglobulin conjugated to horseradish peroxidase (Amersham Corp., Orsay, France). The complete cocktail of protease inhibitors was from Roche Diagnostics (Reinach, Switzerland).
Yeast plasmids
LexA-fused bait and B42-fused prey hsp27 or aB-crystallincoding sequences were cloned into EcoRI/XhoI sites in pEG202 or pJG4-5 plasmids, respectively. Wild-type hsp27 and D100G, C137A, R140G, D51-88 and D141-175 hsp27 mutant complementary DNA were PCR amplified from the pCINeo vectors already described (Gonin et al., 1999; Arrigo et al., 2005) , using forward primer: 5 0 -CGGAATTCATGACC GAGCGCCGCGTCCCC-3 0 and reverse primer: 5 0 -CCCTC GAGCTTTACTTGGCGGCAGTCTCATC-3 0 . pJK103 lexAop-lacZ reporter plasmid has been already described (Estojak et al., 1995) .
Yeast strains
Saccharomyces cerevisiae strains MB210 (MATa leu2::6Lex-Aop-LEU2 ade2::8LexAop-ADE2 his3 trp1 ura3) and MB226 (MATa leu2 ade2 his3 trp1 ura3) were used for the screening. Strains TB50 (MATa) and EGY42 (MATa) were used to confirm interactions (Gyuris et al., 1993) .
Eukaryotic expression vectors
Aptamer DNA sequences from screen-isolated prey plasmids were PCR amplified with specific primers (forward: 5 0 -CC GGAATTCGGATGAGCGACAAGATCA-3 0 and reverse: 5 0 -CGGGGTACCTTAGGCCAGGTTGGC-3 0 ) and cloned into EcoRI/KpnI sites of the pCMV-myc vector (Clontech, SaintGermain-en-Laye, France). The PAs DNA sequences were further EcoRI-NotI digested from pCMV-myc and subcloned in pCIneo vector (Sigma). psuperNeo vector encoding a shRNA27 or a mismatch control RNA will be described elsewhere.
PA selection PA selection was performed using an improved version of the yeast two-hybrid interaction trap, essentially as previously described (Bickle et al., 2006) . Yeast strain MB226a was transformed with pJK103 and pEG202-Hsp27. Yeast strain MB210a was transformed with a mix of randomized 8-mer and 13-mer PA libraries in pWP2 vector (Bickle et al., 2006) . Plasmids containing the selected PAs were recovered from the yeast using phenol/chloroform procedure and transformed into MH3 E. coli strain onto M9 minimal medium. Interactions were confirmed by an interaction mating assay after retransformation of bait and aptamer plasmids in EGY48a and TB50a strains, respectively (Finley and Brent, 1994; Bickle et al., 2006) .
Cell culture and transfections
All cells were grown at 37 1C in a humidified atmosphere containing 5% CO 2 . HeLa and SQ20B cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal calf serum. For transient expression, exponentially growing HeLa cells were seeded at a density of 1.5 Â 10 6 cells/78 cm 2 one night before transfection with 7 mg of DNA, according to the Lipofectamine reagent procedure (Invitrogen). Forty-eight hours after transfection, cells were submitted to the different treatments. Stably transfected SQ20B cells were grown under G418 (600 mg/ml) selection.
